Information: NIBIO
Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine
Apr. 24, 2020
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) and National Institutes of Biomedical Innovation, Health and Nutrition (Headquarters: Ibaraki City, Japan; Director General: Yoshihiro Yoneda) announced today that they have concluded a joint research agreement, aiming at the practical application of a universal influenza vaccine that provides broader protection against most influenza.
please click here for the details.